206 related articles for article (PubMed ID: 35439613)
1. 2021 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2022 Aug; 27(8):2057-2064. PubMed ID: 35439613
[TBL] [Abstract][Full Text] [Related]
2. 2018 in review: FDA approvals of new molecular entities.
Kinch MS; Griesenauer RH
Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
[TBL] [Abstract][Full Text] [Related]
3. Incentives for orphan drug research and development in the United States.
Seoane-Vazquez E; Rodriguez-Monguio R; Szeinbach SL; Visaria J
Orphanet J Rare Dis; 2008 Dec; 3():33. PubMed ID: 19087348
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
5. 2023 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2024 May; 29(5):103966. PubMed ID: 38552777
[TBL] [Abstract][Full Text] [Related]
6. 2020 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2021 Dec; 26(12):2794-2799. PubMed ID: 34252611
[TBL] [Abstract][Full Text] [Related]
7. 2016 in review: FDA approvals of new molecular entities.
Griesenauer RH; Kinch MS
Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
[TBL] [Abstract][Full Text] [Related]
8. Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy.
Michaeli DT; Michaeli T; Albers S; Boch T; Michaeli JC
Eur J Health Econ; 2023 Nov; ():. PubMed ID: 37962724
[TBL] [Abstract][Full Text] [Related]
9. Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022.
Seoane-Vazquez E; Rodriguez-Monguio R; Powers JH
Sci Rep; 2024 Feb; 14(1):3325. PubMed ID: 38336899
[TBL] [Abstract][Full Text] [Related]
10. 2015 in review: FDA approval of new drugs.
Kinch MS
Drug Discov Today; 2016 Jul; 21(7):1046-50. PubMed ID: 27109618
[TBL] [Abstract][Full Text] [Related]
11. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Richey EA; Lyons EA; Nebeker JR; Shankaran V; McKoy JM; Luu TH; Nonzee N; Trifilio S; Sartor O; Benson AB; Carson KR; Edwards BJ; Gilchrist-Scott D; Kuzel TM; Raisch DW; Tallman MS; West DP; Hirschfeld S; Grillo-Lopez AJ; Bennett CL
J Clin Oncol; 2009 Sep; 27(26):4398-405. PubMed ID: 19636013
[TBL] [Abstract][Full Text] [Related]
12. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
13. 2014 in review: FDA approval of new drugs.
Kinch MS
Drug Discov Today; 2017 Apr; 22(4):620-624. PubMed ID: 26100738
[TBL] [Abstract][Full Text] [Related]
14. A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs.
Brown DG
J Med Chem; 2024 Feb; 67(3):1690-1700. PubMed ID: 38233132
[TBL] [Abstract][Full Text] [Related]
15. 2022 in review: FDA approvals of new medicines.
Kinch MS; Kraft Z; Schwartz T
Drug Discov Today; 2023 Aug; 28(8):103622. PubMed ID: 37201782
[TBL] [Abstract][Full Text] [Related]
16. Ophthalmic Drug Discovery in the United States over the past Two Decades.
Gu D; Janetos TM
Ophthalmic Epidemiol; 2021 Feb; 28(1):21-26. PubMed ID: 32597285
[TBL] [Abstract][Full Text] [Related]
17. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
Kerr KW; Glos LJ
Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
[TBL] [Abstract][Full Text] [Related]
18. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
19. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
Kaitin KI; Manocchia M
Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
[TBL] [Abstract][Full Text] [Related]
20. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
Kaitin KI; DiMasi JA
Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]